The female sexual dysfunction treatment market is gaining visibility as research and innovation in women’s health advances, and societal stigmas begin to erode. Characterized by various conditions such as low libido, pain during intercourse, and difficulty in arousal or orgasm, female sexual dysfunction (FSD) affects millions of women worldwide, with both psychological and physiological factors playing a role. The global market is expected to witness rapid growth, expanding at a CAGR of 34.20% during the forecast period of 2025–2034.
To explore related developments in therapeutic innovation and healthcare technology, refer to Expert Market Research.
Female Sexual Dysfunction Treatment Market Size
Despite decades of underrepresentation in women’s sexual health research, the global market is now experiencing a surge in clinical interest and investment. The approval of female-specific medications and growing awareness among patients and healthcare providers are driving demand for treatments that address FSD more holistically.
CAGR (2025–2034): 34.20%
Key Growth Regions: North America, Europe, and Asia Pacific
The expanding body of clinical data supporting treatments for Hypoactive Sexual Desire Disorder (HSDD) and other dysfunctions is fueling the development pipeline and pushing both pharmaceutical and behavioral health sectors to innovate.
Female Sexual Dysfunction Treatment Market Share
The market is segmented across various therapeutic categories and indications, with pharmaceutical interventions and hormonal therapies holding a growing share. However, behavioral and non-hormonal therapies are also gaining traction due to fewer side effects and long-term usability.
By Region:
North America dominates the market owing to early adoption of approved treatments like flibanserin and bremelanotide, strong healthcare infrastructure, and greater public awareness.
Europe follows closely, particularly in countries like Germany and the UK, where pharmaceutical innovation and regulatory support are strong.
Asia Pacific is emerging rapidly, driven by rising healthcare expenditure and cultural shifts promoting more open conversations about female sexual health.
By Key Players:
Companies like Sprout Pharmaceuticals, Pfizer, and AMAG Pharmaceuticals are at the forefront, investing in both drug-based and integrative treatment options to capture a larger market share.
Female Sexual Dysfunction Treatment Market Growth & Trends
Growth Drivers:
Increased Awareness & Diagnosis: Advocacy campaigns, media representation, and broader mental health awareness have led to more women seeking help for FSD.
Approval of Female-Specific Therapies: Products like Addyi (flibanserin) and Vyleesi (bremelanotide) have legitimized FSD as a treatable condition, attracting new entrants to the market.
Advancements in Hormonal Therapies: Hormone-based treatments, especially for postmenopausal women, are being refined for improved safety and efficacy.
Integration of Digital Health Tools: Mobile apps and telemedicine platforms now offer accessible, stigma-free environments for treatment delivery and education.
Market Trends:
Non-Hormonal Innovations: Due to growing safety concerns, non-hormonal therapies, including cognitive behavioral therapy (CBT) and neuromodulation, are gaining popularity.
Personalized Treatment Approaches: Combining therapy, medication, and lifestyle changes is becoming a more widely accepted, effective treatment model.
Increased Investment in Women’s Health Startups: Venture capital interest in female-focused health tech and biopharma is rising steadily.
According to Wikipedia, sexual dysfunction refers to difficulty during any stage of the sexual activity cycle, and for women, the complexity often requires multifaceted treatment approaches.
Female Sexual Dysfunction Treatment Market Case Studies & News
Recent Developments:
Sprout Pharmaceuticals re-launched Addyi, the first FDA-approved treatment for HSDD, with renewed marketing efforts emphasizing safety and patient outcomes.
Bremelanotide (Vyleesi), developed by AMAG Pharmaceuticals, gained attention for offering an on-demand solution for women suffering from low sexual desire.
Emotional Brain BV announced clinical trials for Lybrido and Lybridos, dual-drug therapies targeting different components of sexual response.
Case Example:
In a study conducted at a U.S. women’s health center, a combination of hormonal therapy and psychosexual counseling resulted in a 65% improvement in self-reported sexual function scores among postmenopausal women, demonstrating the effectiveness of integrated treatment models.
Female Sexual Dysfunction Treatment Market Analysis
Competitive Landscape:
The market is currently in a phase of accelerated clinical trials, regulatory approvals, and portfolio expansion. Many pharmaceutical companies are either developing their proprietary treatments or entering licensing and partnership agreements to strengthen their presence.
Key Players:
AMAG Pharmaceuticals Inc.
Sprout Pharmaceuticals, Inc.
Emotional Brain BV
Pivot Pharmaceuticals Inc.
Apricus Biosciences, Inc.
Pfizer, Inc.
Merck & Co., Inc.
Cipla Inc
GlaxoSmithKline, Plc
Duchesnay Inc.
Novo Nordisk AS
These players are investing in R&D, exploring new hormonal combinations, and engaging with regulatory bodies to fast-track approvals.
Regulatory Impacts:
In the U.S., the FDA plays a crucial role in shaping the market by approving therapies with adequate risk–benefit profiles.
EMA (European Medicines Agency) guidelines on female sexual health have catalyzed more research activity across the European market.
In emerging markets, regulatory harmonization and patient advocacy groups are helping to raise awareness and reduce barriers to access.
Female Sexual Dysfunction Treatment Market Segmentation
By Indication:
Hypoactive Sexual Desire Disorder (HSDD): Largest segment; primary target of current FDA-approved drugs.
Arousal Disorder
Penetration (Sexual Pain) Disorder
Female Orgasmic Disorder
Others
By Type:
Counseling and Behavioral Therapy: Often the first line of treatment, especially in psychologically rooted dysfunctions.
Medication: Includes centrally acting agents like flibanserin and bremelanotide.
Non-Hormonal Therapy: Includes SSRIs, bupropion, and pelvic floor therapy.
Hormonal Therapy: Testosterone patches, estrogen creams, and other hormone modulators.
Others: Lifestyle intervention programs, mindfulness-based therapies.
By Age:
18–30 Years: Increasing demand due to lifestyle and stress-induced conditions.
30–45 Years: Largest treatment-seeking group, often influenced by relationship and hormonal factors.
Above 45 Years: Menopause-related sexual dysfunction is prevalent, with hormone replacement therapy often indicated.
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
View More Reports
Osteoporosis Drug Pipeline Analysis Report
India Disposable Medical Gloves Market
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
